Despite encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial difficulty from pharmacy benefit managers. Such organizations are often erecting barriers to reimbursement, such as high price requirements and PA that hinder patient availability. Market believe tha